Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CRAXI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.670
EU - Europa 17.695
AS - Asia 15.992
SA - Sud America 2.451
Continente sconosciuto - Info sul continente non disponibili 1.844
AF - Africa 461
OC - Oceania 53
Totale 80.166
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 41.013
SG - Singapore 6.098
RU - Federazione Russa 4.632
CN - Cina 4.033
IT - Italia 3.724
FI - Finlandia 2.022
BR - Brasile 1.953
HK - Hong Kong 1.580
DE - Germania 1.389
VN - Vietnam 1.352
UA - Ucraina 1.277
PL - Polonia 986
GB - Regno Unito 856
IE - Irlanda 812
FR - Francia 754
BD - Bangladesh 590
JP - Giappone 530
IN - India 377
SE - Svezia 354
KR - Corea 345
CA - Canada 327
TR - Turchia 236
RO - Romania 189
AR - Argentina 157
NL - Olanda 145
MX - Messico 142
IQ - Iraq 137
AT - Austria 101
ZA - Sudafrica 95
CI - Costa d'Avorio 93
BE - Belgio 90
UZ - Uzbekistan 76
ES - Italia 73
PK - Pakistan 69
EC - Ecuador 67
CO - Colombia 65
SA - Arabia Saudita 60
VE - Venezuela 57
CL - Cile 56
ID - Indonesia 55
IR - Iran 54
MA - Marocco 53
EG - Egitto 49
JM - Giamaica 49
PH - Filippine 48
KE - Kenya 45
MY - Malesia 45
AU - Australia 44
CH - Svizzera 39
PY - Paraguay 38
CZ - Repubblica Ceca 37
AZ - Azerbaigian 33
BG - Bulgaria 33
NP - Nepal 33
GR - Grecia 31
TN - Tunisia 28
LB - Libano 27
JO - Giordania 26
AE - Emirati Arabi Uniti 25
CR - Costa Rica 24
DZ - Algeria 24
TH - Thailandia 24
LT - Lituania 22
PE - Perù 22
DK - Danimarca 20
TW - Taiwan 20
BO - Bolivia 18
EU - Europa 18
HN - Honduras 18
AL - Albania 16
KG - Kirghizistan 16
KZ - Kazakistan 16
DO - Repubblica Dominicana 14
GT - Guatemala 14
OM - Oman 14
SN - Senegal 14
TT - Trinidad e Tobago 14
UY - Uruguay 14
BY - Bielorussia 13
PA - Panama 13
IL - Israele 12
NI - Nicaragua 12
GE - Georgia 11
NG - Nigeria 10
PT - Portogallo 10
BA - Bosnia-Erzegovina 9
ET - Etiopia 9
PS - Palestinian Territory 9
RS - Serbia 9
BH - Bahrain 8
MD - Moldavia 8
SV - El Salvador 8
MM - Myanmar 7
SI - Slovenia 7
XK - ???statistics.table.value.countryCode.XK??? 7
AO - Angola 6
BN - Brunei Darussalam 6
GA - Gabon 6
HR - Croazia 6
HU - Ungheria 6
Totale 78.238
Salva come PNG Salva come JPEG
Città #
Fairfield 5.452
Ashburn 4.635
Singapore 4.329
Woodbridge 2.683
San Jose 2.334
Chandler 2.170
Seattle 2.158
Wilmington 2.154
Houston 2.133
Cambridge 1.908
Hong Kong 1.510
Ann Arbor 1.348
Zgierz 881
Palermo 833
Dublin 804
Medford 729
Moscow 713
Jacksonville 659
Beijing 601
Altamura 573
Council Bluffs 554
Des Moines 553
Santa Clara 521
Tokyo 496
Nanjing 491
Los Angeles 489
Helsinki 471
Ho Chi Minh City 462
Princeton 461
Frankfurt am Main 428
New York 425
Lawrence 409
Boardman 408
Lauterbourg 405
San Diego 348
Hanoi 328
Dallas 306
Dearborn 224
Chicago 211
Tulsa 197
The Dalles 182
Buffalo 174
Milan 173
Shenyang 166
São Paulo 161
Hefei 160
London 158
Jinan 155
Nanchang 152
Phoenix 138
Changsha 129
Hebei 116
Tianjin 110
Jiaxing 109
Nuremberg 106
Orem 105
Rome 99
Columbus 98
Ludwigshafen am Rhein 95
Abidjan 93
San Paolo di Civitate 88
Istanbul 87
Zhengzhou 85
Seongnam 83
Brussels 82
Toronto 80
Atlanta 77
Chennai 77
Izmir 74
Warsaw 72
Saint Petersburg 70
Amsterdam 69
Guangzhou 67
Ningbo 66
Haiphong 59
Montreal 59
Munich 57
Brooklyn 56
Denver 55
Paris 55
Rio de Janeiro 55
Falls Church 53
Hangzhou 53
Tashkent 53
Baghdad 52
Da Nang 52
Johannesburg 50
Kumar 50
Mumbai 50
Verona 47
Shanghai 45
Redwood City 44
Springfield 44
Curitiba 43
Poplar 43
Nairobi 42
City of London 41
Venice 41
Auburn Hills 40
Ottawa 40
Totale 51.829
Salva come PNG Salva come JPEG
Nome #
EASL Clinical Practice Guidelines: management of hepatitis C virus infection 413
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 399
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 356
Alexithymia and personality traits of patients with inflammatory bowel disease 347
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 343
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 335
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 333
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 330
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 326
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 323
Hepatitis B virus reactivation and alemtuzumab therapy 317
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 317
HCV genotypes in Sicily: is there any evidence of a shift? 315
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 311
Clinical course and management of acute and chronic viral hepatitis during pregnancy. 306
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 306
Clinical course and genetic susceptibility of primary biliary cirrhosis: Analysis of a prospective cohort 302
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 301
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 300
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 297
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 294
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response 291
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 284
Characteristics of liver cirrhosis in Italy: results from a multicenter national study 282
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 282
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 280
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 279
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 277
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 276
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 269
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 267
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 265
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 263
Clinical implications of the hyperdynamic syndrome in cirrhosis. 263
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract 262
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 261
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 261
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 258
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 257
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 256
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 256
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. 254
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 253
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 252
Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases 251
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 251
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 251
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 249
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 249
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 246
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 246
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 246
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 245
Adefovir for lamivudine resistant HBV: More than meets the eye. 243
Clinical trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. 243
Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis 243
Acute hepatitis C: in search of the optimal approach to cure. 242
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 242
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 241
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 241
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 238
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 237
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 237
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis 235
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 235
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 234
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 233
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 233
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 232
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 232
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 231
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 231
A patient with acute hepatitis C and possible IFN toxicity [2] 231
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 231
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 230
Coeliac disease: Oral ulcer prevalence, assessment of risk and association with gluten-free diet in children. 228
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 228
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. 228
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy 227
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis 227
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis 226
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 226
Hepatitis B virus reactivation and alemtuzumab therapy 226
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 226
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 225
ATTUALI ORIENTAMENTI NELLA DIAGNOSTICA DELLA MALATTIA DI HIRSCHSPRUNG 224
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 223
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 222
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 221
Genetic predisposition to thrombophilia in inflammatory bowel disease 221
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 221
Oral Mucosa of celiac disease patients produces anti-endomysial and anti-transglutaminase antibodes. Diagnostic usefulness of an in vitro culture system 219
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 219
A woman with a long history of abdominal pain 219
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 218
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 218
PEG IFN alfa-2a vs. alfa-2b: And the winner is ...? 217
Phylogenetic Reconstruction of HCV Genotype 1b Dissemination in a Small City Centre: The Camporeale Model 217
Halitosis: could it be more than mere bad breath? 217
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 215
Totale 26.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 279.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 279.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.198 0 1.147 159 148 154 230 279 410 686 637 383 965
2022/20236.755 759 1.533 114 648 701 1.047 402 457 683 48 254 109
2023/20242.362 139 416 162 195 196 514 231 138 42 54 18 257
2024/20257.000 197 424 422 734 192 235 426 467 560 881 889 1.573
2025/202627.305 1.523 726 1.370 1.986 2.511 4.037 3.756 2.810 2.604 3.594 1.317 1.071
2026/20271.729 1.535 194 0 0 0 0 0 0 0 0 0 0
Totale 80.166